DNA microarray analysis of white adipose tissue from obese (fa/fa) Zucker rats treated with a beta3-adrenoceptor agonist, KTO-7924

Area of Science:

• Metabolic research
• Adipose tissue biology
• Pharmacology

Background:

• Obesity is linked to disrupted lipid metabolism and insulin resistance.
• White adipose tissue (WAT) dysfunction contributes to metabolic disorders.
• Targeting adrenoceptors offers a potential therapeutic strategy for obesity.

Purpose of the Study:

• To investigate the effects of KTO-7924, a beta3-adrenoceptor agonist, on lipid metabolism and gene expression in obese Zucker rats.
• To determine if KTO-7924 can induce brown adipose tissue (BAT)-like characteristics in white adipose tissue (WAT).

Main Methods:

• Oral administration of KTO-7924 to obese Zucker rats for 28 days.
• Measurement of retroperitoneal white adipose tissue (RP WAT) weight, plasma lipid profiles, and insulin levels.
• DNA microarray analysis to assess mRNA expression in RP WAT.
• Oral glucose tolerance tests (OGTT) to evaluate insulin resistance.

Main Results:

• KTO-7924 treatment significantly reduced RP WAT weight, plasma triglyceride, free fatty acid, and insulin levels.
• Improved insulin sensitivity was observed in KTO-7924-treated rats during OGTT.
• DNA microarray identified increased mRNA expression of uncoupling protein 1 (UCP1) and cytochrome c oxidase subunit VIII-H (COX8H) in RP WAT.
• These genes, typically found in BAT, were upregulated by KTO-7924, suggesting a browning effect.

Conclusions:

• KTO-7924 effectively improves lipid metabolism and insulin resistance in obese Zucker rats.
• Beta3-adrenoceptor stimulation with KTO-7924 promotes the development of BAT-like adipocytes within RP WAT.
• This suggests a potential therapeutic role for KTO-7924 in managing obesity-related metabolic dysfunction.